Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium.

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2025-05-14 DOI:10.3390/curroncol32050278

Catherine C Fahey, Sean Clark-Garvey, Sima Porten, Ashish M Kamat, Thomas W Flaig, John A Taylor, William Y Kim, Matthew I Milowsky

引用次数: 0

Abstract

Enfortumab vedotin (EV) in combination with pembrolizumab (P) has led to a new paradigm for the treatment of metastatic urothelial carcinoma (mUC). Since the presentation of the results of the EV-302 trial at the European Society of Medical Oncology 2023 annual meeting, the entire treatment landscape for mUC has been upended. At the 2024 Albert Symposium, we reviewed ongoing research investigating predictive biomarkers for EV response and resistance as well as clinical trials exploring the potential role for EV in different clinical disease states including non-muscle invasive and muscle-invasive disease.

查看原文本刊更多论文

在尿路上皮癌中，Enfortumab Vedotin的机制见解和未来方向：来自Leo & Anne Albert研究所第10届年度膀胱癌护理和研究研讨会的亮点。

Enfortumab vedotin （EV）联合pembrolizumab (P)为转移性尿路上皮癌（mUC）的治疗提供了新的范例。自EV-302试验结果在欧洲肿瘤医学学会2023年年会上公布以来，mUC的整个治疗前景已经被颠覆。在2024年Albert Symposium上，我们回顾了正在进行的关于EV反应和耐药的预测性生物标志物的研究，以及探索EV在不同临床疾病状态（包括非肌肉侵袭性和肌肉侵袭性疾病）中的潜在作用的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.